Therapies targeting DNA damage response show promising antitumor activity
Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers—ATR inhibitor elimusertib and PARP inhibitor AZD5305—are safe and clinically beneficial in treating ...
Apr 11, 2022
0
4